

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/587,867

Filing Date January 31, 2005

First Named Inventor Link et al.

Art Unit Not Yet Known

Examiner Name Not Yet Known

Attorney Docket Number 53526AUSM1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	PTO-1449 With Cited Refs.
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Return Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Berlex Biosciences.		
Signature			
Printed name	Jacqueline S. Larson		
Date	Oct. 13, 2006	Reg. No.	30,279

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Alishia L. Rowe-Babb	Date	10-13-06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Link et al.

:Group Art Unit: Not Yet Known

Application No.: 10/587,867

:Examiner: Not Yet Known

Filed: January 31, 2005

:Docket No. 53526AUSM1

For: SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

Mail Stop: PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 1.97 through 1.98, Applicants wish to make known to the Patent and Trademark Office the references cited from a foreign patent office on the attached form PTO-1449 (copies enclosed).

As to any reference supplied, Applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with Applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, Applicants believe that their invention is patentable.

This Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits as described in 37 CFR 1.97(b). Therefore, it is believed that no fee is required under 37 CFR 1.97(b)(3). However, the Commissioner is hereby authorized to charge any additional fees required to facilitate the filing of this application to deposit account 02-2117. This is, however, not authorization to charge the issue fee.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully Submitted,
BERLEX BIOSCIENCES
Customer No. 27586

Jacqueline S Larson

Jacqueline S. Larson (Reg. No. 30,279)
Patent Attorney for Applicants

Date: Oct. 13, 2006

Berlex Biosciences
2600 Hilltop Drive
P.O. Box 4099
Richmond, California 94804-0099
Telephone No. 510-669-4483
Facsimile No. 510-262-7095

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 53526AUSM1		APPLICATION NO. 10/587,867	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Link et al.			
				FILING DATE January 31, 2005		GROUP ART UNIT Not Yet Known	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		US 6,608,030	Aug. 19. 03	Ploegh et al.			
		US 7,101,880	Sept. 05. 06	Graupe et al.			
		US2005/0182096	Aug. 18. 05	Link et al			
		US2003/232864	Dec. 18. 03	Link et al			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
		WO02/20485	Mar. 14. 02	PCT			
		WO03/029200	Apr. 10. 03	PCT			
		WO02/20002	Mar. 14. 02	PCT			
		WO04/083182	Sept. 30. 04	PCT			
		WO04/028521	Apr. 08. 04	PCT			
		WO05/028429	Sept. 17. 04	PCT			
		WO06/034006	Sept. 16. 05	PCT			
		WO04/00838	Dec. 31. 03	PCT			
		WO04/108661	Dec. 16. 04	PCT			
		WO02/098850	Dec. 12. 02	PCT			
		WO05/028454	Sept. 17. 04	PCT			
		WO05/058348	Dec. 10. 04	PCT			
		WO05/063742	Dec. 22. 04	PCT			
		WO05/074904	Jan. 31. 05	PCT			
		WO06/060494	Dec. 01. 05	PCT			
		WO00/55144	Sept. 21.00	PCT			
		WO01/19796	Mar. 22. 01	PCT			
		WO03/024924	Mar. 27.03	PCT			
		WO04/033445	Apr. 22. 04	PCT			

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
53526AUSM1APPLICATION NO.
10/587,867**INFORMATION
DISCLOSURE STATEMENT**
(Use several sheets if necessary)APPLICANTS
Link et al.FILING DATE
January 31, 2005GROUP ART UNIT
Not Yet Known

		WO03/097617	Nov. 27. 03	PCT		
		WO06/102423	Mar. 23. 06	PCT		
		WO01/19816	Mar. 22. 01	PCT		
		WO00/51998	Sept. 8. 00	PCT		
		WO02/069901	Sept. 12. 02	PCT		
		WO06/102535	Mar. 22. 06	PCT		
		WO06/060810	Dec. 01. 05	PCT		
		WO06/034004	Sept. 16. 05	PCT		
		WO06/102243	Mar. 17. 06	PCT		
		EP 1 516 877	Mar. 23. 05	EP		
		EP 0 623 627	Nov. 09. 94	EP		

	7	Riese et al., "Cathepsin S Activity Regulates Antigen Presentation and Immunity." <i>Journal of Clinical Investigation</i> , Pages 2351-2363, June 1998.
	8	Saegusa et al., "Cathepsin S Inhibitor Prevents Autoantigen Presentation and Autoimmunity." <i>Journal of Clinical Investigation</i> , Vol. 110, No.3, Pages 361-369, August 2002.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applican(s).